SQZ BIOTECH
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
SQZ BIOTECH
Industry:
Biotechnology Life Science Therapeutics
Founded:
2013-01-01
Address:
Watertown, Massachusetts, United States
Country:
United States
Website Url:
http://www.sqzbiotech.com
Total Employee:
101+
Status:
Active
Contact:
617-758-8672
Email Addresses:
[email protected]
Total Funding:
229.81 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
National Institute of General Medical Science
National Institute of General Medical Science investment in Grant - SQZ Biotech
Invus
Invus investment in Series D - SQZ Biotech
Polaris Partners
Polaris Partners investment in Series D - SQZ Biotech
Illumina Ventures
Illumina Ventures investment in Series D - SQZ Biotech
JDRF T1D Fund
JDRF T1D Fund investment in Series D - SQZ Biotech
GV
GV investment in Series D - SQZ Biotech
NanoDimension
NanoDimension investment in Series D - SQZ Biotech
Temasek Holdings
Temasek Holdings investment in Series D - SQZ Biotech
GV
GV investment in Series D - SQZ Biotech
Alumni Ventures
Alumni Ventures investment in Series D - SQZ Biotech
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-11 | SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer |
Official Site Inspections
http://www.sqzbiotech.com Semrush global rank: 9.59 M Semrush visits lastest month: 136
- Host name: chi205.greengeeks.net
- IP address: 108.178.7.22
- Location: Chicago United States
- Latitude: 41.8777
- Longitude: -87.6376
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60604
More informations about "SQZ Biotech" on Search Engine
SQZ Biotech
SQZ Biotech. SQZ Biotechnologies Company. PO Box 5515. Wayland, MA 01778. On March 4, 2024, SQZ Biotechnologies Company sold substantially all of its assets, including intellectual property and Cell Squeeze® …See details»
‘Not all rainbows and unicorns’ — a former CEO dishes on his …
Sep 7, 2023 Switzerland’s Roche, like many companies its size, was making big moves in cell therapy, and saw potential in SQZ’s platform for immuno-oncology. In 2015, Roche …See details»
SQZ Biotechnologies | LinkedIn
SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases.See details»
SQZ Biotech - Funding, Financials, Valuation & Investors
SQZ Biotech is registered under the ticker NYSE:SQZ . Their stock opened with $16.00 in its Oct 29, 2020 IPO. SQZ Biotech is funded by 22 investors. National Institute of …See details»
SQZ Biotechnologies Company (SQZB) - Yahoo Finance
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious …See details»
STEMCELL Technologies Announces Successful Asset …
Feb 29, 2024 VANCOUVER, British Columbia, February 29, 2024 -- ( BUSINESS WIRE )--STEMCELL Technologies is pleased to announce the acquisition of substantially all …See details»
SQZ Biotechnologies seeks to expand the universe of …
SQZ Biotechnologies has taken a unique approach to overcome these limitations, creating a novel platform technology that can accommodate a wide range of cells and cargo enabling development...See details»
SQZBiotechnologiesseekstoexpand theuniverseofcelltherapies
SQZ Biotechnologies seeks to expand the universe of cell therapies. Potential game-changing Cell Squeeze technology opens up cell therapy to diverse cells and cargoes in …See details»
SQZ Biotech - SQZ Biotechnologies Initial First-In-Human Data ...
Jun 4, 2021 WATERTOWN, Mass.-- (BUSINESS WIRE)-- SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple …See details»
Vancouver-based STEMCELL Technologies Announces Asset …
Vancouver, BC, March 3, 2024--Vancouver-based STEMCELL Technologies announced the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a …See details»
SQZ founder Armon Sharei opens new Portal to cell engineering
Dec 12, 2023 SQZ Biotech Cell & Gene Therapy Bayer Roche. As SQZ Biotechnologies slips away, the biotech’s founder and former CEO Armon Sharei, Ph.D., is launching a new cell engineering platform...See details»
SQZ Biotech - SQZ Biotechnologies Appoints Micah Zajic as …
Appointment Effective July 11, 2022. WATERTOWN, Mass.-- (BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for …See details»
Roche puts up $125M to expand SQZ cell therapy pact - Fierce …
Oct 15, 2018 Roche has committed $125 million in upfront and near-term payments to expand its partnership with SQZ Biotechnologies. The revised deal sets Roche up to …See details»
SQZ Biotech, breaking convention, hits the NYSE with $71M IPO
Oct 30, 2020 Armon Sharei (SQZ Biotech) When it’s time to go public, most biotech companies opt for the Nasdaq. Not so for cell therapy-focused SQZ Biotech, which raised $71 million in its New York...See details»
Canada’s largest biotech pays $11.8M for assets of SQZ
Mar 4, 2024. Listen to this article 3 min. After announcing it was laying off most of its remaining staff in November, SQZ Biotechnologies Co. is now selling off its assets. …See details»
SQZ Biotech - SQZ Biotechnologies Announces Healthcare …
Jan 6, 2022 WATERTOWN, Mass.-- (BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic …See details»
Roche Partners with SQZ Biotech in $500M+ Cell Therapy …
December 7, 2015. Roche will partner with SQZ Biotech to develop a cell therapy platform that would empower a patient’s own immune cells to fight a broad range of cancers, in an …See details»
SQZ Biotechnologies Company (SQZB) - Stock Analysis
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates. WATERTOWN, Mass.-- (BUSINESS WIRE)--SQZ Biotechnologies Company …See details»
SQZ CEO steps down as company restructures, cuts jobs
Published Dec. 1, 2022. Ned Pagliarulo Lead Editor. Leonid Sorokin via Getty Images. SQZ Biotechnologies, a small Watertown, Mass.-based biotechnology company, will lay off …See details»
SQZ Biotech signs up to $1bn immuno-oncology deal with Roche
Cell therapy company SQZ Biotechnologies has expanded its deal worth up to $1bn with Roche for the development and commercialisation of immune-oncology products. SQZ and Roche initially partnered in 2015 to formulate drugs from …See details»